2

[ttweed@wildrockies.org (Tony Tweedale)]

          "Plant-Based Estrogen Has Fewer Side Effects."  USA Today, 8
          December 97, 1D.
               Harry K. Genant, director of the osteoporosis research group
               at the University of California, San Francisco, reports that
               Estratab, a low-dose form of estrogen derived from soybeans
               and yams, helps strengthen bones without the negative side
               effects of higher-dose estrogen.  His study appears in
               _Archives of Internal Medicine_ [which the OPPT Library does
               not receive].


          "Estrogen-Mimicking Drug Obtains FDA Approval [National News
          Briefs]."  New York Times, 11 December 97, A20.  "Osteoporosis
          Drug [Findings]."  Washington Post, 11 December 97, A4.  "Lilly's
          Osteoporosis Drug is Approved by the FDA, Sparking Marketing
          War."  Wall Street Journal, 11 December 97, B14.
               Raloxifene has received FDA approval and will be marketed by
               Eli Lilly under the trade name Evista. The drug does not
               protect bone mass quite as well as estrogen but it does not
               carry the same risks.